Intellipharmaceutics International Inc. (IPCI)

[cysonic]

Yes, that's possible for sure. But that's a typical risk in biotech - it has nothing to do with IPCI in particular. And remember: we are valued at 80 million $ and are near break-even even without Rexista. So I don't see a "catastrophic" downside risk here. BUT: If Rexista gets approved with a wide labelling, we might gap up to a valuation multiple times higher than today. So great risk/reward ratio imho.

cysonic